Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stephen Hilbert
AddedFeb 15, 2024
UpdatedMay 31, 2026
Stephen Hilbert

Stephen Hilbert

Board Member, Kineta

Crunchbase

Stephen Hilbert's Career

Kineta
Kineta

Seattle, WA, US

Board Member· Board
Immusoft
Immusoft

Seattle, WA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stephen Hilbert's Career

Kineta
Kineta
Acquired$98M02008Seattle, WA, US
Board Member· Board

Leadership at Kineta

Charles MagnessCharles MagnessCo-Founder
Daniel TardiffDaniel TardiffCo-Founder
Shawn IadonatoShawn IadonatoCEO
David ArkowitzDavid ArkowitzBoard Member

Similar to Kineta

NantkwestNantkwestCulver City, CA, USCancer Treatment, Immunotherapyest. 2014NantkwestCulver City, CA, US · est. 2014

ImmunityBio, Inc.: A US-based biotech firm specializing in immunotherapy for cancer and infectious diseases.

Public · $103.5M51
ImmunomeImmunomeExton, PA, USCancer Therapiesest. 2008ImmunomeExton, PA, US · est. 2008

Immunome, a Philadelphia-based biotech company, develops innovative cancer immunotherapies.

Public · $218.9M48
SynthekineSynthekineMenlo Park, CA, USTherapeutics, Treatmentsest. 2018SynthekineMenlo Park, CA, US · est. 2018

US-based Synthekine engineers cytokines to develop transformative treatments for cancer and autoimmune disorders.

Series C · $289.5M122
Cleveland BioLabsCleveland BioLabsFort Collins, CO, USImmunotherapiesest. 2003Cleveland BioLabsFort Collins, CO, US · est. 2003

Biotech research agency restoring immune health through safe drugs.

Public · $112.2M75
Immusoft
Immusoft
Series A$49.3M222009Seattle, WA, US
Board Member· Board

Leadership at Immusoft

Sean AinsworthSean AinsworthBoard Member
Julia MooreJulia MooreBoard Member
Mark AhnMark AhnBoard Member
Matthew ScholzMatthew ScholzBoard Member
Tony SunTony SunBoard Member

Similar to Immusoft

ImmunoVecImmunoVecSanta Monica, CA, USGene Therapyest. 2019ImmunoVecSanta Monica, CA, US · est. 2019

Santa Monica-based ImmunoVec develops gene therapy treatments for terminal immune system diseases.

Series A · $4.3M6
ImmunisImmunisIrvine, CA, USStem Cell Therapiesest. 2018ImmunisIrvine, CA, US · est. 2018

Immunis: A private biotech firm innovating stem cell treatments for age and disease-related immunity decline.

Series A · $10M8
InimmuneInimmuneMissoula, MT, USImmunotherapeuticsest. 2016InimmuneMissoula, MT, US · est. 2016

Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.

Series A · $22.6M15
IM TherapeuticsIM TherapeuticsAurora, CO, USTherapiesest. 2015IM TherapeuticsAurora, CO, US · est. 2015

IM Therapeutics: Pioneering HLA-directed platform for innovative therapies in autoimmune diseases.

Series A · $10M5

Stephen Hilbert's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Stephen Hilbert

Stephen RubinoStephen RubinoBoard Member · Viracta TherapeuticsPamela BushPamela BushBoard Member · CvergenxAsh KhannaAsh KhannaBoard Member · Pivotal bioVenture PartnersDuane SwordDuane SwordBoard Member · Kuva SystemsChris WilfongChris WilfongCo-Founder · 76BioBill BaumBill BaumBoard Member · Gevo